Danaher (NYSE:DHR) Issues Earnings Results

Danaher (NYSE:DHR) posted its quarterly earnings data on Tuesday. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20, Briefing.com reports. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the firm earned $2.36 earnings per share. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year.

Danaher Stock Down 1.8 %

NYSE DHR traded down $4.68 during trading on Wednesday, hitting $248.43. The stock had a trading volume of 1,005,983 shares, compared to its average volume of 2,754,582. The company’s 50-day moving average price is $248.95 and its two-hundred day moving average price is $230.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The company has a market capitalization of $183.97 billion, a PE ratio of 39.74, a P/E/G ratio of 3.96 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Insider Activity

In related news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock worth $8,265,802 in the last quarter. Corporate insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of recent research reports. Robert W. Baird boosted their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday. Raymond James upped their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Barclays increased their price target on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 10th. KeyCorp upped their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada boosted their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $268.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.